Haleon Pakistan Restricted has authorised a £3.58 million funding to broaden and modernize its Panadol Liquid packaging line, as the corporate strikes to spice up capability and meet rising demand within the client healthcare market.
In response to a disclosure submitted to the Pakistan Inventory Trade, the funding was authorised by the corporate’s board of administrators and will likely be used to obtain superior packaging equipment, improve current infrastructure, and strengthen high quality management techniques.
The corporate stated the enlargement is geared toward enhancing operational effectivity whereas enhancing manufacturing functionality for Panadol Liquid, one among its key over-the-counter merchandise in Pakistan.
Haleon Pakistan stated the initiative displays its long-term development technique and continued concentrate on innovation within the client healthcare section.
The disclosure acknowledged that the undertaking will contain modernisation of the present packaging line, permitting the corporate to reply extra successfully to market demand and preserve product high quality requirements.
Haleon Pakistan is a part of Haleon plc, a world client healthcare firm shaped following the demerger of GSK’s client healthcare enterprise. The group’s portfolio consists of well-known manufacturers reminiscent of Panadol, Centrum, and Sensodyne.